TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.
HGSC
HRD
TCR clonality
biomarkers
prognostic
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Aug 2021
31 Aug 2021
Historique:
received:
27
07
2021
revised:
20
08
2021
accepted:
27
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Immune infiltration is a prognostic factor in high-grade serous ovarian carcinoma (HGSC) but immunotherapy efficacy is disappointing. Genomic instability is now used to guide the therapeutic value of PARP inhibitors. We aimed to investigate exome-derived parameters to assess the tumor microenvironment according to genomic instability profile. We used the HGSC TCGA (the cancer genome atlas) dataset with genomic characteristics, including homologous recombination deficiency (HRD), copy number variant (CNV) signatures, TCR (T cell receptor) clonality and abundance of tissue-infiltrating immune and stromal cell populations. We then investigated the relationship with survival data. In 578 HGSC patients, HRD status, CNV signature 7 and TCR clonality were associated with longer survival. The combination of high CNV signature 7 expression and HRD status or high CNV signature 3 expression and high TCR clonality was associated with a trend towards longer survival compared to each variable alone. Combining T cell infiltrate and TCR clonality improved the prognostic value compared to T cells infiltration alone. Prognostic value of TCR clonality was confirmed in an independent cohort. TCR clonality is an emerging prognostic biomarker that improves T cell infiltrate information. Analysis of TCR clonality combined with genomic instability could be an interesting prognostic biomarker.
Identifiants
pubmed: 34503204
pii: cancers13174394
doi: 10.3390/cancers13174394
pmc: PMC8430641
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Genome Res. 2014 Nov;24(11):1881-93
pubmed: 25060187
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Bioinformatics. 2015 May 15;31(10):1526-35
pubmed: 25573922
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
J Clin Oncol. 2021 Jun 10;39(17):1842-1855
pubmed: 33891472
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813239
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Mod Pathol. 2009 Mar;22(3):393-402
pubmed: 19060844
Gynecol Oncol. 2018 Oct;151(1):10-17
pubmed: 30078505
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Neoplasia. 2018 Mar;20(3):280-288
pubmed: 29466768
NPJ Breast Cancer. 2018 Jul 2;4:16
pubmed: 29978035
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Mod Pathol. 2012 May;25(5):740-50
pubmed: 22282309
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
Lancet. 2021 Jan 23;397(10271):281-292
pubmed: 33485453
Onco Targets Ther. 2019 Nov 11;12:9527-9538
pubmed: 31807028
Nat Genet. 2018 Sep;50(9):1262-1270
pubmed: 30104763
Nat Commun. 2020 Mar 19;11(1):1459
pubmed: 32193378
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Cell Rep. 2018 Apr 03;23(1):239-254.e6
pubmed: 29617664
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
Clin Cancer Res. 2020 Mar 15;26(6):1359-1371
pubmed: 31831563
Cancers (Basel). 2021 Apr 20;13(8):
pubmed: 33924213
Ann Oncol. 2020 Dec;31(12):1606-1622
pubmed: 33004253
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Oncotarget. 2020 Jul 07;11(27):2669-2683
pubmed: 32676168